الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 78 |  |  |
| | | from | 78 | | |
Abstract
Malignant pleural effusions continue to be a common problem in patients with metastatic disease, leading to a significant reduction in quality of life secondary to symptoms such as dyspnea and cough. The treatment of malignant pleural effusions is palliative, and should be directed at improving the quality of life with minimal complications.
The aim of pleurodesis in these patients is to prevent reaccumulation of the effusion and thereby of symptoms, and avoid the need for repeated hospitalization for thoracocentesis.
A wide variability exists in the choices of sclerosing agents. Talcum powder, tetracycline and bleomycin have been widely used for pleurodesis. Considering these agents, Povidone-iodine (an iodine based topical antiseptic) is extensively used as a sclerosing agent. Many studies have shown the effectiveness of Povidone-iodine to achieve a complete response of rates 80-90% in the management of pleural effusion.
Our study was carried on total number of 39 patients. The patients were divided into two groups. Group A consisted of 21 patients who underwent Talc powder pleurodesis. Group B consisted of 18 patients who underwent Povidone-iodine pleurodesis. Data from the 39 patients were analyzed.
The aim of this study was to compare the efficacy, safety, and outcome of Talc powder pleurodesis versus Povidone—iodine pleurodesis through a chest tube as a palliative treatment for preventing recurrence of malignant pleural effusion.
Summary
Page 58
Follow up was assessed post-procedure and in our outpatient clinic with evaluation of patients’ symptoms regarding follow-up chest X-ray.
Results that emerged from our study comparing our experience with the pleurodesis technique in recurrent malignant effusion between both groups:
(1) This study shows no statistical difference in success rate between the use of talc powder, which is considered to be the standard treatment and the use of Povidone—iodine as a sclerosing agent.
(2) Our study revealed that Povidone—iodine has a good success rate with few minor complications, can be infused through intercostal chest tube and repeated if necessary.
(3) There was no significant statistical difference between the two groups regarding post-operative complications and the hospital stay.
Results during post-pleurodesis follow-up, along with others published by many authors, seem to be encouraging, and push up to keep on performing Povidone-iodine pleurodesis in cases with recurrent malignant effusion.